| 51 |
Cadence Pharmaceuticals Inc. et al v. Agila Specialties Inc. et al |
1:14-cv-01499 |
D.Del. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
| 52 |
Cadence Pharmaceuticals Inc. et al v. Agila Specialties Inc. et al |
1:14-cv-01499 |
D.Del. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
| 53 |
Fresenius Kabi USA, LLC v. Mylan Laboratories Limited et al |
1:14-cv-00205 |
N.D.W.Va. |
|
|
|
|
| 54 |
AbbVie Inc. v. Mylan Pharmaceuticals Inc. et al |
1:14-cv-01236 |
D.Del. |
|
|
|
|
| 55 |
OTSUKA PHARMACEUTICAL CO., LTD. v. MYLAN INC. et al |
1:14-cv-04508 |
D.N.J. |
|
|
|
|
| 56 |
AstraZeneca AB et al v. Mylan Laboratories Limited et al |
1:12-cv-00300 |
D.Del. |
|
|
|
|
| 57 |
AstraZeneca AB et al v. Mylan Laboratories Limited et al |
1:12-cv-00300 |
D.Del. |
|
|
|
|
| 58 |
AstraZeneca AB et al v. Mylan Laboratories Limited et al |
1:12-cv-00300 |
D.Del. |
|
|
|
|
| 59 |
AstraZeneca AB et al v. Mylan Laboratories Limited et al |
1:12-cv-00300 |
D.Del. |
|
|
|
|
| 60 |
AstraZeneca AB et al v. Mylan Laboratories Limited et al |
1:12-cv-00300 |
D.Del. |
|
|
|
|